Malaria Vaccine Type | Usage | Precautions | Side Effects
- Malaria is caused by four or five species of a parasite Plasmodium.
P.falciparum is the specie responsible for most of the severe cases of malaria.
- The disease is endemic in mainly tropic and sub-tropic regions of the world, and is a major cause of morbidity and mortality globally.
- Currently there is no vaccine available against malaria for commercial or routine use.
- RTS, S/AS01 is the only vaccine against malaria which has completed phase 3 trials.
- It is a recombinant protein based vaccine capable of providing protection against P.falciparum but not against P.vivax.
- WHO has recommended pilot vaccination projects using RTS, S/AS01 in some areas of sub-Saharan Africa.
- If licensed, this will be the first ever vaccine licensed against a disease caused by a parasite.
- Reports from the Phase 3 trials conducted on about 15000 children in various countries of Africa divided into two age groups (6-14 weeks and 5-17 months old) were published in April 2015.
- These reports estimated the efficacy of the vaccine to be around 30% in preventing severe malaria, with variations among the two age groups.